For Immediate Release
Oak Brook, IL – The July special issue of SLAS Discovery, “Functional Genomics for Target Identification,” features ten articles focused on three strategic pillars that form the foundation of the functional genomics discipline.
Functional genomics screens allow researchers to systematically disrupt large numbers of genes or proteins in order to reveal cellular phenotypes that enable gene function. Recent research shows that functional genomics has great potential for both the dissection of molecular mechanisms of human diseases and the reduction of the very high attrition rate in the drug discovery process. The long-term success of functional genomics platforms in addressing these challenges will be driven by advancements in the three strategic pillars highlighted within this issue.
Special issue editors Davide Gianni, Ph.D., (AstraZeneca, United Kingdom) and Stuart Farrow, Ph.D., (CRUK Therapeutic Discovery Laboratories, United Kingdom) selected research reviews and articles that cover a variety of relevant topics, including:
Access to July’s SLAS Discovery issue is available at https://journals.sagepub.com/toc/jbxb/25/6 through August 20. For more information about SLAS and its journals, visit www.slas.org/publications/slas-discovery/.
SLAS (Society for Laboratory Automation and Screening) is an international community of 16,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.195. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-seven Therapeutics, Boston, MA (USA).
SLAS Technology: Translating Life Sciences Innovation, 2019 Impact Factor 2.174. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).
Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103